# Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

> **NCT03824405** · PHASE2 · COMPLETED · sponsor: **Botanix Pharmaceuticals** · enrollment: 200 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** BTX 1204
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT03824405
- **Lead sponsor:** Botanix Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-04
- **Primary completion:** 2020-01-27
- **Final completion:** 2020-03-04
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2022-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03824405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03824405, "Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03824405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*